ICU sedation, delirium & recovery
Efficacy of Ramelteon, Suvorexant, and Lemborexant for Delirium Prevention in Hospitalized Patients: A Systematic Review and Meta-Analysis
Authors' conclusion
Sleep-wake regulating pharmacologic agents were associated with 40%-46% relative risk reductions in delirium prevalence, based on low-certainty evidence.
Study context
- Population
- Hospitalized adults
- Participants
- 4,489 adults · 24 studies
- Comparison
- Suvorexant, lemborexant or ramelteon vs control
- Sleep-wake regulating agentsn = 1,752
- Outcome
- Delirium prevalence
Methodological detailsrandom-effects meta-analysis, GRADE certainty assessment
- Random-effects meta-analysis
- GRADE certainty assessment
Pooled result
As reported in the abstract
Randomized trials: RR
0.60
95% CI 0.38–0.97; low certainty
Observational studies: RR
0.54
95% CI 0.43–0.68; low certainty
Further pooled results
Delirium prevalence by individual agent (subgroup)
- No credible subgroup effects by individual agent
- Interaction p > 0.1
- Exploratory analyses
Ventilator days, mortality, hospital or ICU LOS
- No significant effects
- Very low certainty
Original publication
Efficacy of Ramelteon, Suvorexant, and Lemborexant for Delirium Prevention in Hospitalized Patients: A Systematic Review and Meta-Analysis. Crit Care Med. Published 13 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →